Exploring Editas Medicine’s Research Pipeline
Editas Medicine’s (EDIT) core capability in genome editing makes use of clustered, regularly interspaced, short palindromic repeats (or CRISPR) technology to create molecules that can specifically edit DNA. Ocular diseases and engineered cell medicines are two areas in which Editas’s research programs have matured. Editas Medicine aims to file an investigational new drug application for this program by mid-2018.